Table 3.
Clinical characteristics at baseline, at month 3 (M3) and at month 6 (M6)
| Baseline | M3 | M6 | |
|---|---|---|---|
| N | 162 | 162 | 134 |
| MMD [mean ± SD] | 18.0 ± 7.5 | 9.8 ± 9.0 | 7.3 ± 7.6 |
| MHD [mean ± SD] | 23.3 ± 6.9 | 15.0 ± 10.5 | 12.5 ± 10.0 |
| Intensities [mean ± SD] | n = 113/162 | n = 114/162 | n = 96/134 |
| Mild days/month | 4.3 ± 6.3 | 6.1 ± 8.4 | 6.0 ± 8.4 |
| Moderate days/month | 8.3 ± 7.5 | 4.9 ± 6.2 | 3.4 ± 4.3 |
| Severe days/month | 9.3 ± 8.1 | 2.9 ± 5.4 | 2.2 ± 4.1 |
| MAMI [mean ± SD] |
18.9 ± 8.0 n = 153/162 |
11.1 ± 9.3 n = 147/162 |
9.4 ± 8.9 n = 129/134 |
| Medication overuse [n (%)] | 107 (66.5) | 57 (35.2) | 37 (27.8) |
| HIT-6 [mean ± SD] |
65.9 ± 7.8 n = 141/162 |
57.1 ± 11.9 n = 135/162 |
55.2 ± 11.1 n = 114/134 |
| MIDAS [mean ± SD] |
80.3 ± 71.3 n = 129/162 |
45.2 ± 62.0 n = 121/162 |
34.4 ± 48.1 n = 101/134 |
| PGIC [mean ± SD] | - |
3.78 ± 2.0 n = 130/162 |
4.13 ± 2.1 n = 110/134 |
| Concomitant oral treatment [n (%)] | 102 (63.0) | 89 (55.3) | 64 (47.8) |
| Concomitant onabotulinum toxin A [n (%)] | 31 (19.1) | 25 (15.5) | 18 (13.4) |
MMD monthly migraine days, SD standard deviation, MHD monthly headache days, MAMI monthly acute medication intake
Missing data is shown below each variable